GLPG0555 / Galapagos, Gilead - LARVOL DELTA

First key steps in pipeline rebuild and strong commercial progress in H1 2022 (GlobeNewswire) - "Galapagos NV...today announced its first half-year 2022 financial results...Pipeline update:...Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis"

Discontinued • Idiopathic Pulmonary Fibrosis • Inflammatory Bowel Disease • Osteoarthritis

Galapagos 2021 results set stage for future growth (GlobeNewswire) - "Galapagos NV...presents financial results 2021, reviews key events for the company, and provides outlook for 2022....Outlook 2022...Our R&D expenditure in 2021 amounted to €491.7 million, compared to €523.7 million in 2020. This decrease was primarily due to the winding down of the programs with...and GLPG1972 (OA), and reduced spend on our other programs....Within our broader inflammation portfolio, we expect the read out from a Phase 1b trial with JAK1 inhibitor GLPG0555 in osteoarthritis and from multiple Phase 1 trials in healthy volunteers."

Discontinued • P1 data • Immunology • Inflammation • Osteoarthritis